摘要
目的:了解CK7、CK20及TTF-1在腺癌中的表达情况,探讨联合应用这3种标志物对判断转移性腺癌原发部位的价值。方法:采用组织芯片和免疫组织化学的方法,检测CK7、CK20与TTF-1在229例腺癌及10例食管鳞癌组织中的表达。结果:3种抗体在不同组织来源肿瘤中的表达可以组合成8种模式:CK7+/CK20-/TTF-1+:甲状腺乳头状癌阳性率较高(50%);CK7+/CK20-/TTF-1-:涎腺腺癌(94.44%)、乳腺小叶癌(85.71%)、卵巢浆液性癌(71.43%)、胆囊腺癌(63.64%)、宫颈腺癌(61.54%),阳性率较高;CK7+/CK20+/TTF-1+:阳性率均不高;CK7+/CK20+/TTF-1-:阳性率均不高;CK7-/CK20-/TTF-1+:阳性率均不高;CK7-/CK20-/TTF-1-:前列腺癌(100%)、食管鳞癌(100%)、肾透明细胞癌(90.90%),阳性率较高;CK7-/CK20+/TTF-1+:阳性率均不高;(CK7-/CK20+/TTF-1-:肠腺癌(66.67%)阳性率较高;结论:联合检测(CK7、CK20及TTF-1抗体有助于判断部分转移性腺癌的器官来源,缩小原发肿瘤的搜寻范围。
Objectives： To investigate the expression of CK7, CK20, and TTF-1 in adenocarcinoma, and summarize a valuable regular pattern to determine their organic source. Methods： A total of 229 cases of adenocarcinoma tumor tissues and 10 cases of esoph- ageal squamous cell carcinoma were studied by the tissue array technology and immunohistochemistry for CK7, CK20, and TTF-1. Re- suits： Eight types of combined patterns of CK7, CK20, and TTF-1 in different cancers were observed： CK7＋ / CK20- / TTF-1 ＋： papil- lary thyroid carcinoma （ 50 % ）; CK7＋ / CK20- / TTF-1-： salivary gland adenocarcinoma （ 94.44 % ）, lobular carcinoma （ 85.71% ）, ovarian serous carcinoma （ 71.43 % ）, gallbladder adenocarcinoma （ 63.64 % ）, and cervical adenocarcinoma （ 61.54 % ）, high positive rates; CK7＋ / CK20＋ / TTF-1＋： none had a high positive rate; CK7＋ / CK20＋ / TTF-1-： none had a high positive rate; CK7- / CK20-/ TTF-1＋： none had a positive rate; CK7-/CK20-/TTF-1-： prostate cancer （ 100 % ）, esophageal squamous cell carcinoma （ 100 % ）, and renal cell carcinoma （ 90.90 % ）, high positive rates; CK7＋/CK20＋/TTF-1 ＋ ： none had a positive rate; and CK7-/CK20＋/ TTF-1-： intestinal adenocarcinoma （ 66.67 % ）, high positive rate. Conclusion： The combined detection of CK7, CK20, and TTF-1 ex- pression helps determine the origins of some metastatic adenocarcinomas, minimize the range of such origins, and establish the ground- work for the origin evaluation of adenocarcinomas.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2012年第10期683-686,共4页
Chinese Journal of Clinical Oncology
